Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 354 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Polyethylene glycol (PEG) Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely

NCT00889655
View directory record Official record
Conditions
Colonoscopy
Interventions
Golytely (polyethylene glycol), MiraLax (polyethylene glycol 3350)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Sep 26, 2026, 1:46 AM EDT
Recruiting Phase 2 Interventional

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT00501826
View directory record Official record
Conditions
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 26, 2026, 1:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

NCT06598007
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
CT3001, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Drug
Lead sponsor
Crossignal Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects

NCT03202927
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PEGFILGRASTIM
Drug
Lead sponsor
Adello Biologics, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Not applicable Interventional

Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy

NCT03247595
View directory record Official record
Conditions
Colonoscopy
Interventions
Magnesium Citrate Capsules, Polyethylene Glycol 3350, Dulcolax Tablets
Dietary Supplement · Other
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 26, 2026, 1:46 AM EDT
Terminated Phase 2 Interventional Results available

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

NCT03531827
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms
Interventions
enzalutamide, CRLX101
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 26, 2026, 1:46 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)

NCT04789044
View directory record Official record
Conditions
Peripheral Nerve Injuries
Interventions
NTX-001
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Baltimore, Maryland • Camden, New Jersey • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 2 Interventional

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

NCT00008463
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
24
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 1 Interventional

Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas

NCT06132165
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser, 755nm Alexandrite Laser
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 3 Interventional

A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

NCT00160602
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Montgomery, Alabama • Sun City West, Arizona • Palm Desert, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Results available

Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit

NCT04210427
View directory record Official record
Conditions
Cystic Fibrosis Gastrointestinal Disease
Interventions
Polyethylene Glycol 3350, SmartPill Motility System & PillCam Patency Capsule
Drug · Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 40 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 3 Interventional

BLI-800-302: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy

NCT00503815
View directory record Official record
Conditions
Colonoscopy
Interventions
BLI-800, Polyethylene glycol 3350 based bowel preparation
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
10
States / cities
Anaheim, California • Orange, California • Jackson, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2007 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Results available

Envarsus in Delayed Graft Function (E-DGF)

NCT03864926
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Envarsus XR, Tacrolimus
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of an Edible Colonoscopy Preparation

NCT03332485
View directory record Official record
Conditions
Colon Prep for Colonoscopy
Interventions
ECP Colon Prep Kit, MoviPrep®
Drug
Lead sponsor
Sebela Pharmaceuticals Development LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
8
States / cities
Anaheim, California • Indianapolis, Indiana • Bastrop, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 26, 2026, 1:46 AM EDT
Terminated Phase 3 Interventional Results available

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

NCT00349752
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol 400 mg, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 4 Interventional

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions
Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
Drug
Lead sponsor
Jeffrey Curtis
Other
Eligibility
18 Years to 85 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 26, 2026, 1:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Polyethylene Glycol Safety in Children

NCT05424757
View directory record Official record
Conditions
Polyethylene Glycols, Children, Only
Interventions
PEG 3350
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 16 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

NCT06028438
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Nipocalimab, Certolizumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Phoenix, Arizona • Huntington Beach, California • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Morning-Only 4 L PEG vs Split Dose Prep for Afternoon Colonoscopies, Endoscopist-Blinded Prospective Study

NCT02643316
View directory record Official record
Conditions
Colonoscopy
Interventions
Same day 4 L preparation (Polyethylene Glycol), Split dose 4 L preparation (Polyethylene Glycol)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision

NCT00627302
View directory record Official record
Conditions
Myopia
Interventions
PEG-400, Systane
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2008 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Results available

Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery

NCT06159777
View directory record Official record
Conditions
Constipation, Surgical Procedure, Unspecified, Prolapse; Female
Interventions
Polyethylene Glycol 3350
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy

NCT01170754
View directory record Official record
Conditions
Colon Cancer
Interventions
PEG-3350 and Gatorade, Golytely 4 liters
Drug
Lead sponsor
Temple University
Other
Eligibility
40 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Results available

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

NCT00160706
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol (CDP870)
Biological
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Results available

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

NCT03357471
View directory record Official record
Conditions
Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
Interventions
e-Device
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Sep 26, 2026, 1:46 AM EDT